News

LLY plans $3.83B in biotech buyouts to expand into vaccines and infectious diseases beyond obesity and diabetes.

Pharmaceutical companies have spent years targeting a common blood particle associated with heart-attack risks.

Hims & Hers Health shares have slumped in 2026 as the telehealth provider moves away from selling compounded GLP-1 medications.

NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock comparison.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

By Rishika Sadam and Sai Ishwarbharath B HYDERABAD/BENGALURU, May 27 (Reuters) - U.S. carrier American Airlines Group plans to double headcount at its India technology hub to about 800 by early next

As Lilly completes the pivotal program for its “triple-G” drug, Phase 1 data from Kailera partner Hengrui suggest their offering might spur greater weight loss.

Semiconductor powerhouse Micron Technology Inc. (NASDAQ:MU) vaulted on Tuesday, officially crossing the $1 trillion market capitalization milestone following a rally driven by demand for artificial intelligence (AI). Historic Market Cap Milestone The shares of the Idaho-based chipmaker closed 19.29% higher at $895.88, locking in a final market value of $1.010 trillion. According to data from CompaniesMarketCap, this monumental surge enabled Micron Technology to comfortably overtake legacy giants

BofA cut its HIMS price target to $25 from $28, while warning that the company’s 2026 outlook depends on a “significant” ramp-up in GLP-1 growth.

Surging demand for the memory chipmaker's AI products has sent its stock soaring. But a rally this steep doesn't come without risk.

Eli Lilly's fair value estimate has shifted slightly from US$1,209.21 to US$1,211.03 per share, a small move that still reflects meaningful debate around what is already priced into the stock. Much of the recent analyst discussion links this updated target range to retatrutide Phase 3 data, with bulls highlighting GLP-1 leadership and bears questioning how much future obesity growth is already embedded. As you read on, you will see how these competing views shape the evolving narrative around...

Investors remained hopeful about U.S.-Iran talks, offsetting recent military exchanges.

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.7% an

Micron (MU) is having its best trading day since 2011, on track to close at a valuation of $1 trillion, which would make its market cap nearly tied with those of Eli Lilly (LLY) and Berkshire Hathaway (BRK-B, BRK-A). Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at Micron's market action in the video above.

Eli Lilly agreed to buy three vaccine developers targeting shingles, bacterial infections and Epstein-Barr Virus.

Why Analysts See Eli Lilly as a Long-Term Winner in the Weight-Loss Race

Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the

Weight-loss drugs such as Novo Nordisk's Ozempic and Wegovy are disrupting eating habits, and restaurants should prepare for changes, an analyst says. More than half of Americans taking GLP-1 drugs including Eli Lilly's Mounjaro have changed their eating habits, a survey by UBS found. "Our survey results suggest GLP-1 users are more likely to eat less calories while taking GLP-1 drugs, with survey respondents dining out less, changing eating habits, and appreciating healthier foods more," UBS analysts led by Dennis Geiger said in a note to clients.

Walmart (NasdaqGS:WMT) is set to enter the top 10 of the Russell 3000 Index during the June 2026 reconstitution, replacing Eli Lilly. The index change follows Q1 results where Walmart reported record sales alongside a cautious earnings outlook that triggered a sharp stock pullback. Two senior executives are leaving the company as Walmart reshapes its leadership team and refines its long term priorities. For you as an investor, Walmart sits at the crossroads of big box retail, grocery, and e...

Eli Lilly (NYSE:LLY) announced a US$3.8b series of acquisitions in vaccines, including Curevo, LimmaTech Biologics, and Vaccine Company. The company is expanding its presence in infectious disease prevention alongside its established obesity and diabetes drug portfolio. Phase 3 trial results for Eli Lilly’s obesity drug candidate retatrutide showed record weight loss outcomes and strong efficacy signals. These developments introduce fresh data points for investors tracking Eli Lilly’s R&D...

(Bloomberg) -- Eli Lilly & Co. is on a record spending spree, announcing acquisitions worth more than $20 billion so far in 2026 as the drugmaker expands beyond its blockbuster obesity franchise. Most Read from BloombergIran’s Khamenei Says No Going Back for Middle East Rocked by WarUS Strikes Targets in Iran Even as Trump Hails Progress on DealRussia Tells US to Evacuate Its Diplomats and Citizens From KyivThese AI Gurus Are Charging Wall Street Banks $25,000 a DayPutin Signs Law on Use of Army

Positive Phase 1b results support plans for a Phase 2 trial later this year.

The drugmaker is buying three vaccine developers to strengthen its infectious disease pipeline.

Eli Lilly and Co (NYSE:LLY) has announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics AG, and Vaccine Company, in transactions valued at up to $3.83 billion combined, as the company expands its research and development efforts into infectious disease...

The Nasdaq Composite and S&P 500 were up, while the Dow Jones Industrial Average was down slightly t

After a brief cool-off last week, U.S. semiconductor and memory stocks are rallying in Tuesday morning trading, led by Micron, which traded above a $1 trillion market capitalization for the first time.

Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.

Micron stock rose after UBS said the AI boom has changed the memory chip market — and tripled its price target to a Street high.

Micron stock rose after UBS said the AI boom has changed the memory chip market — and tripled its price target to a Street high.

Micron stock rose after UBS said the AI boom has changed the memory chip market — and tripled its price target to a Street high.